Three CD19-targeting CAR T-cells were initially approved by the Food and Drug Administration (FDA) for the management of patients with R/R DLBCL after the failure of at least two previous treatment lines: axicabtagene ciloleucel (axi-cel), tisagenlecleucel (tisa-cel), and lisocabtagene maraleucel (liso-cel). The gene discussed is CD19; the disease is diffuse large B-cell lymphoma.